title: Organ preservation with concurrent chemoradiation for advanced laryngeal cancer: are we succeeding?
abstract: OBJECTIVE
  To determine the rates of organ preservation and function in patients with advanced laryngeal and hypopharyngeal carcinomas treated with concurrent chemoradiotherapy (CRT).
  
  
  METHODS
  Between April 1999 and September 2005, 82 patients with advanced laryngeal (67%) and hypopharyngeal carcinomas (33%) underwent conventional radiotherapy and concurrent platinum-based chemotherapy with curative intent. Sixty-two patients were male (75.6%). The median age was 59 years. Eighteen patients (22%) were in Stage III and 64 (78%) were in Stage IV. The median radiation dose was 70 Gy. The median potential follow-up was 3.9 years.
  
  
  RESULTS
  Overall survival and disease-free survival were respectively 63% and 73% at 3 years. Complete response rate from CRT was 75%. Nineteen patients (23%) experienced significant long-term toxicity after CRT: 6 (7.3%) required a percutaneous endoscopic gastrostomy, 5 (6%) had persistent Grade 2 or 3 dysphagia, 2 (2.4%) had pharyngoesophageal stenosis requiring multiple dilations, 2 (2.4%) had chronic lung aspiration, and 7 (8.5%) required a permanent tracheostomy. Four patients (4.9%) underwent laryngectomy without pathologic evidence of disease. At last follow-up, 5 (6%) patients were still dependent on a gastrostomy. Overall, 42 patients (52%) were alive, in complete response, with a functional larynx and no other major complications.
  
  
  CONCLUSIONS
  In our institution, CRT for advanced hypopharyngeal and laryngeal carcinoma has provided good overall survival and locoregional control in the majority of patients, but a significant proportion did not benefit from this approach because of either locoregional failure or late complications. Better organ preservation approaches are necessary to improve locoregional control and to reduce long-term toxicities.
authors.affiliation: Department of Radiation Oncology, CHUM - Hôpital Notre-Dame, Montreal, Quebec, Canada. louise.lambert@gmail.com
authors.forename: Louise
authors.initials: L
authors.lastname: Lambert
authors.forename: Bernard
authors.initials: B
authors.lastname: Fortin
authors.forename: Denis
authors.initials: D
authors.lastname: Soulières
authors.forename: Louis
authors.initials: L
authors.lastname: Guertin
authors.forename: Geneviève
authors.initials: G
authors.lastname: Coulombe
authors.forename: Danielle
authors.initials: D
authors.lastname: Charpentier
authors.forename: Jean-Claude
authors.initials: JC
authors.lastname: Tabet
authors.forename: Manon
authors.initials: M
authors.lastname: Bélair
authors.forename: Nader
authors.initials: N
authors.lastname: Khaouam
authors.forename: Phuc Felix
authors.initials: PF
authors.lastname: Nguyen-Tan
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use; D016190:Carboplatin / Q000627:therapeutic use; D002945:Cisplatin / Q000627:therapeutic use; D003131:Combined Modality Therapy / Q000009:adverse effects / Q000379:methods / Q000401:mortality; D018572:Disease-Free Survival; D005260:Female; D005774:Gastrostomy / Q000706:statistics & numerical data; D006801:Humans; D007012:Hypopharyngeal Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy*; D007822:Laryngeal Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy*; D008297:Male; D008875:Middle Aged; D011879:Radiotherapy Dosage; D014139:Tracheostomy / Q000706:statistics & numerical data
chemical_list: D000970:Antineoplastic Agents; D016190:Carboplatin; D002945:Cisplatin